Developing imaging technologies for therapeutic interventions in rare diseases (BIOIMAGE-NMD)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2013
  • Initiating Organization: European Commission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • Rare disease
  • Disease focus:
    Muscular Dystrophy
  • Location: Europe

Abstract

The overarching objective of the BIOIMAGE-NMD project is to deliver combined structural and molecular imaging biomarkers with proven utility for the detection of therapeutic effects in patients with rare neuromuscular diseases (NMDs).

Mission

The project will have three specific objectives:

Financing

Funding is provided by the Seventh Framework Programme of the European Union. 

Other website

http://www.treat-nmd.eu/about/related-projects/bioimage-nmd/

Sponsors & Partners

CRIS

Institute of Myology Paris

Leids Universitair Medisch Centrum

Newcastle University

Prosensa Therapeutics

SCITO

Universita Cattolica del Sacro Cuore of Milan

University College London

University Hospitals Leuven


Last Updated: 04/14/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.